ACAD logo

ACADIA PHARMACEUTICALS INC

ACADNASDAQ
🏆 #1582 by market capUS Equity
$20.20▼ $0.32 (−1.56%)
After hours · at close
🔔
Track ACAD
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.6%
7d▼ 23.5%
14d▼ 24.5%
30d▼ 30.7%
ytd▼ 24.3%
1y▼ 5.4%
🏦Market Cap
$3.46B
Small Cap
📈Revenue Growth (YoY)
+47.0%
High Growth
📊Gross Margin
91.1%
High
💵FCF Margin
17.4%
Healthy
⚖️P/S Ratio
3.1x
Fair
Otter Score
84
Good

Trading Snapshot

Day Range
$20.04 – $20.31
52-Week Range
$19.69 – $30.96
Volume
$2.52B
Avg Volume
$2.56B
Shares Outstanding
171.2M
Next Earnings
Oct 19, 2026

Fundamentals Snapshot

Annual Revenue
$1.07B
Last Q Revenue
$308M
P/E Ratio
9.2
P/S Ratio
3.1x
EPS (TTM)
$2.21
Dividend Yield
—
Dilution (1yr)
+3.0%

Why Investors Own ACAD

  • ✓High-growth profile — revenue up +59.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 44% gross margin and 23% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ACAD logo

ACADIA PHARMACEUTICALS INC

ACAD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.1B▲ +11.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
91.7%▲ +0.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$105M▼ −54.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$105M▼ −33.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
171.4M▲ +3.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$126M▼ −$142M YoY
StockOtter · stockotter.space

About ACADIA PHARMACEUTICALS INC

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
84/100

Analyst Price Target

ⓘ
Average Target
$24.32
▲ +20.4% Upside
High Target$27.39
Low Target$18.01
Based on 39 analysts

Latest News & Updates

🚀
Reuters·2h ago

ACADIA PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift ACAD price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

ACADIA PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.